{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:50:45Z","timestamp":1782384645030,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Fundacao para a Ciencia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R37 GM076343"],"award-info":[{"award-number":["R37 GM076343"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM007767"],"award-info":[{"award-number":["T32 GM007767"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006206","name":"Biological and Environmental Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dmd.2026.100300","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:27:18Z","timestamp":1776144438000},"page":"100300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural context of NADPH-cytochrome P450 reductase mutations that alter cytochrome P450 1A2 substrate regioselectivity"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-9761","authenticated-orcid":false,"given":"Sarah D.","family":"Burris-Hiday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-1313","authenticated-orcid":false,"given":"Francisco","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-0076","authenticated-orcid":false,"given":"Michel","family":"Kranendonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-5716","authenticated-orcid":false,"given":"Emily E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.dmd.2026.100300_bib1","doi-asserted-by":"crossref","first-page":"12808","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100300_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.abb.2012.09.002","article-title":"NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family","volume":"528","author":"Iyanagi","year":"2012","journal-title":"Arch Biochem Biophys"},{"issue":"16","key":"10.1016\/j.dmd.2026.100300_bib3","doi-asserted-by":"crossref","first-page":"8411","DOI":"10.1073\/pnas.94.16.8411","article-title":"Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes","volume":"94","author":"Wang","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"10.1016\/j.dmd.2026.100300_bib4","doi-asserted-by":"crossref","first-page":"16246","DOI":"10.1074\/jbc.M111.230532","article-title":"Conformational changes of NADPH-cytochrome P450 oxidoreductase are essential for catalysis and cofactor binding","volume":"286","author":"Xia","year":"2011","journal-title":"J Biol Chem"},{"issue":"4-5","key":"10.1016\/j.dmd.2026.100300_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jmb.2012.03.022","article-title":"The closed and compact domain organization of the 70-kDa human cytochrome P450 reductase in its oxidized state as revealed by NMR","volume":"420","author":"Vincent","year":"2012","journal-title":"J Mol Biol"},{"issue":"17","key":"10.1016\/j.dmd.2026.100300_bib6","doi-asserted-by":"crossref","first-page":"11374","DOI":"10.1074\/jbc.M807868200","article-title":"Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450","volume":"284","author":"Hamdane","year":"2009","journal-title":"J Biol Chem"},{"issue":"52","key":"10.1016\/j.dmd.2026.100300_bib7","doi-asserted-by":"crossref","first-page":"36628","DOI":"10.1074\/jbc.M109.054304","article-title":"Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering","volume":"284","author":"Ellis","year":"2009","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100300_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jinorgbio.2009.12.017","article-title":"Cross-linking of human cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: identification of a potential site of interaction","volume":"104","author":"Bumpus","year":"2010","journal-title":"J Inorg Biochem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2013.01.010","article-title":"NADPH P450 oxidoreductase: structure, function, and pathology of diseases","volume":"138","author":"Pandey","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100300_bib10","first-page":"241","article-title":"Antley-Bixler syndrome: case report and review of the literature","volume":"6","author":"Poddevin","year":"1995","journal-title":"Genetic Counseling"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib11","first-page":"397","article-title":"Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures","volume":"11","author":"Antley","year":"1975","journal-title":"Birth Defects Original Article Series"},{"issue":"1","key":"10.1016\/j.dmd.2026.100300_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/jmg.37.1.26","article-title":"Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?","volume":"37","author":"Reardon","year":"2000","journal-title":"J Med Genet"},{"issue":"9427","key":"10.1016\/j.dmd.2026.100300_bib13","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(04)16503-3","article-title":"Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study","volume":"363","author":"Arlt","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100300_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ng1300","article-title":"Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome","volume":"36","author":"Fluck","year":"2004","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.dmd.2026.100300_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1086\/429417","article-title":"Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis","volume":"76","author":"Huang","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"1-2","key":"10.1016\/j.dmd.2026.100300_bib16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.mce.2010.10.022","article-title":"Consequences of POR mutations and polymorphisms","volume":"336","author":"Miller","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100300_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/FPC.0b013e32830054ac","article-title":"Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19","volume":"18","author":"Agrawal","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"10.1016\/j.dmd.2026.100300_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/FPC.0b013e32833f4f9b","article-title":"Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro","volume":"20","author":"Sandee","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.dmd.2026.100300_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbrc.2010.09.035","article-title":"Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism","volume":"401","author":"Fluck","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"18","key":"10.1016\/j.dmd.2026.100300_bib20","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.3390\/ijms21186669","article-title":"Interaction modes of microsomal cytochrome P450s with its reductase and the role of substrate binding","volume":"21","author":"Esteves","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2026.100300_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fphar.2020.00299","article-title":"The role of the FMN-domain of human cytochrome P450 oxidoreductase in its promiscuous interactions with structurally diverse redox partners","volume":"11","author":"Esteves","year":"2020","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100300_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105112","article-title":"Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain","volume":"299","author":"Burris-Hiday","year":"2023","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.dmd.2026.100300_bib23","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1021\/acs.biochem.1c00178","article-title":"Structural dynamics of cytochrome P450 3A4 in the presence of substrates and cytochrome P450 reductase","volume":"60","author":"Ducharme","year":"2021","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.dmd.2026.100300_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100210","article-title":"Mass spectrometry footprinting reveals microsomal CYP2A6 structural changes induced by interaction with its reductase flavin mononucleotide domain","volume":"54","author":"Chai","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100300_bib25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/biom13071083","article-title":"Single mutations in cytochrome P450 oxidoreductase can alter the specificity of human cytochrome P450 1A2-mediated caffeine metabolism","volume":"13","author":"Esteves","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1124\/pr.117.014407","article-title":"Interindividual differences in caffeine metabolism and factors driving caffeine consumption","volume":"70","author":"Nehlig","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1383-5718(98)00193-4","article-title":"Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: comparison of three types of expression systems","volume":"439","author":"Kranendonk","year":"1999","journal-title":"Mutation Research"},{"key":"10.1016\/j.dmd.2026.100300_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcp.2018.10.006","article-title":"Human cytochrome P450 expression in bacteria: whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4","volume":"158","author":"Esteves","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100300_bib29","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1074\/jbc.M115.677294","article-title":"Cytochrome P450 17A1 Interactions with the FMN domain of its reductase as characterized by NMR","volume":"291","author":"Estrada","year":"2016","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/jsbi.1996.0048","article-title":"Crystallization and preliminary X-ray diffraction studies of human cytochrome P450 reductase","volume":"116","author":"Zhao","year":"1996","journal-title":"Journal of Structural Biology"},{"issue":"Pt 2","key":"10.1016\/j.dmd.2026.100300_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDX","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 4","key":"10.1016\/j.dmd.2026.100300_bib32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J Appl Crystallogr"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1110\/ps.8.2.298","article-title":"Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution","volume":"8","author":"Zhao","year":"1999","journal-title":"Protein Sci"},{"issue":"Pt 4","key":"10.1016\/j.dmd.2026.100300_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 2","key":"10.1016\/j.dmd.2026.100300_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 12 Pt 1","key":"10.1016\/j.dmd.2026.100300_bib36","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1107\/S0907444904026460","article-title":"Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions","volume":"60","author":"Krissinel","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.dmd.2026.100300_bib37","series-title":"The PyMOL Molecular Graphics System","year":"2017"},{"issue":"19","key":"10.1016\/j.dmd.2026.100300_bib38","doi-asserted-by":"crossref","first-page":"14348","DOI":"10.1074\/jbc.M611692200","article-title":"Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2","volume":"282","author":"Sansen","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/dmd.109.030445","article-title":"Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect","volume":"38","author":"Marohnic","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100300_bib40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fphar.2017.00580","article-title":"Altered CYP19A1 and CYP3A4 activities due to mutations A115V, T142A, Q153R and P284L in the human P450 oxidoreductase","volume":"8","author":"Udhane","year":"2017","journal-title":"Front Pharmacol"},{"issue":"29","key":"10.1016\/j.dmd.2026.100300_bib41","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1021\/bi00195a024","article-title":"Probing the putative cytochrome P450- and cytochrome c-binding sites on NADPH-cytochrome P450 reductase by anti-peptide antibodies","volume":"33","author":"Shen","year":"1994","journal-title":"Biochemistry"},{"issue":"4-5","key":"10.1016\/j.dmd.2026.100300_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jsbmb.2009.11.010","article-title":"Sequence-function correlation of aromatase and its interaction with reductase","volume":"118","author":"Hong","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100300_bib43","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.bbapap.2010.02.003","article-title":"Beta sheet 2-alpha helix C loop of cytochrome P450 reductase serves as a docking site for redox partners","volume":"1804","author":"Jang","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"89","key":"10.1016\/j.dmd.2026.100300_bib44","doi-asserted-by":"crossref","first-page":"13422","DOI":"10.1039\/C9CC05904K","article-title":"Probing protein-protein and protein-substrate interactions in the dynamic membrane-associated ternary complex of cytochromes P450, b(5), and reductase","volume":"55","author":"Gentry","year":"2019","journal-title":"Chem Commun (Camb)"},{"issue":"28","key":"10.1016\/j.dmd.2026.100300_bib45","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1074\/jbc.M116.724625","article-title":"Mutants of cytochrome P450 reductase lacking either Gly-141 or Gly-143 destabilize its FMN semiquinone","volume":"291","author":"Rwere","year":"2016","journal-title":"J Biol Chem"},{"issue":"Pt 2","key":"10.1016\/j.dmd.2026.100300_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1107\/S2059798316016314","article-title":"Combining X-ray and neutron crystallography with spectroscopy","volume":"73","author":"Kwon","year":"2017","journal-title":"Acta Crystallogr D Struct Biol"},{"issue":"39","key":"10.1016\/j.dmd.2026.100300_bib47","doi-asserted-by":"crossref","first-page":"13488","DOI":"10.1074\/jbc.RA120.014087","article-title":"X-ray-induced photoreduction of heme metal centers rapidly induces active-site perturbations in a protein-independent manner","volume":"295","author":"Pfanzagl","year":"2020","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100300_bib48","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/pro.3661","article-title":"Structural insight into the high reduction potentials observed for Fusobacterium nucleatum flavodoxin","volume":"28","author":"Mothersole","year":"2019","journal-title":"Protein Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0026-895X(25)10337-4","article-title":"Differences in the mechanism of functional interaction between NADPH-cytochrome P-450 reductase and its redox partners","volume":"30","author":"Tamburini","year":"1986","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100300_bib50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0003-9861(88)90358-X","article-title":"Role of electrostatic interactions in the reaction of NADPH-cytochrome P-450 reductase with cytochromes P-450","volume":"261","author":"Nadler","year":"1988","journal-title":"Arch Biochem Biophys"},{"issue":"46","key":"10.1016\/j.dmd.2026.100300_bib51","doi-asserted-by":"crossref","first-page":"27475","DOI":"10.1074\/jbc.270.46.27475","article-title":"Role of acidic residues in the interaction of NADPH-cytochrome P450 oxidoreductase with cytochrome P450 and cytochrome c","volume":"270","author":"Shen","year":"1995","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.dmd.2026.100300_bib52","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1016\/S0021-9258(19)67801-4","article-title":"Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase","volume":"266","author":"Shimizu","year":"1991","journal-title":"J Biol Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:24:10Z","timestamp":1782383050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0090955626000693"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100300","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural context of NADPH-cytochrome P450 reductase mutations that alter cytochrome P450 1A2 substrate regioselectivity","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100300"}}